Bit Capital Gmb H Ascendis Pharma A/S Transaction History

Bit Capital Gmb H

$1.26 Trillion
Q4 2024

A detailed history of Bit Capital Gmb H transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Bit Capital Gmb H holds 73,990 shares of ASND stock, worth $8.84 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares

73,990

Previous 68,421 8.14%

Holding current value

$8.84 Million

Previous $10.2 Billion 0.29%

% of portfolio

0.81%

Previous 0.95%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$122.0 - $146.6 $679,418 - $816,415	5,569 Added 8.14%	73,990 $10.2 Billion
Q3 2024 Feb 12, 2025	SELL	$113.0 - $153.43 $4.09 Million - $5.56 Million	-36,217 Reduced 34.61%	68,421 $10.2 Billion
Q2 2024 Feb 12, 2025	SELL	$121.07 - $153.67 $605,350 - $768,349	-5,000 Reduced 4.56%	104,638 $14.3 Billion
Q1 2024 Feb 12, 2025	BUY	$123.45 - $159.4 $5.94 Million - $7.67 Million	48,108 Added 78.19%	109,638 $16.6 Billion
Q4 2023 Feb 12, 2025	BUY	$86.1 - $127.36 $4.51 Million - $6.67 Million	52,407 Added 574.45%	61,530 $7.75 Billion
Q2 2023 Feb 12, 2025	BUY	$69.96 - $97.84 $118,931 - $166,328	1,700 Added 22.9%	9,123 $814 Million
Q1 2023 Feb 12, 2025	BUY	$104.9 - $126.78 $46,680 - $56,417	445 Added 6.38%	7,423 $796 Million
Q4 2022 Feb 12, 2025	BUY	$99.42 - $131.97 $223,595 - $296,800	2,249 Added 47.56%	6,978 $852 Million
Q3 2022 Feb 12, 2025	BUY	$84.03 - $110.23 $330,153 - $433,093	3,929 Added 491.13%	4,729 $488 Million
Q1 2022 Feb 12, 2025	BUY	$102.18 - $135.75 $81,744 - $108,600	800 New	800 $93.9 Million

Others Institutions Holding ASND

# of Institutions

238

Shares Held

58.7M

Call Options Held

205K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $6.67B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bit Capital Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Bit Capital Gmb H with notifications on news.

Account